Asad Haider
Stock Analyst at Goldman Sachs
(4.46)
# 1,036
Out of 4,407 analysts
110
Total ratings
83.3%
Success rate
20.2%
Average return
Main Sectors:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintained: Buy | $275 | $240.87 | +14.17% | 19 | Jun 11, 2026 | |
| LLY Eli Lilly and Company | Rated: Buy | $1,283 | $1,133.00 | +13.24% | 22 | Jun 8, 2026 | |
| PFE Pfizer | Maintained: Hold | $26 | $26.21 | -0.80% | 17 | Jun 8, 2026 | |
| MRK Merck & Co. | Maintained: Buy | $137 | $119.05 | +15.08% | 17 | Jun 2, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $61 | $57.13 | +6.77% | 10 | May 28, 2026 | |
| RPRX Royalty Pharma | Rated: Buy | $51 → $59 | $54.87 | +7.53% | 3 | May 7, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintained: Hold | $37 → $38 | $30.40 | +25.00% | 4 | May 7, 2026 | |
| INVA Innoviva | Maintained: Sell | $17 → $18 | $22.74 | -20.84% | 2 | May 6, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $132 → $133 | $90.54 | +46.90% | 5 | May 5, 2026 | |
| ABBV AbbVie | Rated: Hold | $223 → $244 | $227.73 | +7.14% | 6 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $38 → $67 | $47.46 | +41.17% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $270 | $355.20 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $66 | $10.09 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $168 | $146.18 | n/a | 1 | Dec 14, 2018 |
Johnson & Johnson
Jun 11, 2026
Maintained: Buy
Price Target: $275
Current: $240.87
Upside: +14.17%
Eli Lilly and Company
Jun 8, 2026
Rated: Buy
Price Target: $1,283
Current: $1,133.00
Upside: +13.24%
Pfizer
Jun 8, 2026
Maintained: Hold
Price Target: $26
Current: $26.21
Upside: -0.80%
Merck & Co.
Jun 2, 2026
Maintained: Buy
Price Target: $137
Current: $119.05
Upside: +15.08%
Bristol-Myers Squibb Company
May 28, 2026
Maintained: Hold
Price Target: $61
Current: $57.13
Upside: +6.77%
Royalty Pharma
May 7, 2026
Rated: Buy
Price Target: $51 → $59
Current: $54.87
Upside: +7.53%
NewAmsterdam Pharma Company
May 7, 2026
Maintained: Hold
Price Target: $37 → $38
Current: $30.40
Upside: +25.00%
Innoviva
May 6, 2026
Maintained: Sell
Price Target: $17 → $18
Current: $22.74
Upside: -20.84%
BioNTech SE
May 5, 2026
Maintained: Buy
Price Target: $132 → $133
Current: $90.54
Upside: +46.90%
AbbVie
Apr 29, 2026
Rated: Hold
Price Target: $223 → $244
Current: $227.73
Upside: +7.14%
Feb 26, 2026
Maintained: Hold
Price Target: $38 → $67
Current: $47.46
Upside: +41.17%
Dec 16, 2019
Upgraded: Buy
Price Target: $270
Current: $355.20
Upside: n/a
Dec 16, 2019
Upgraded: Buy
Price Target: $66
Current: $10.09
Upside: n/a
Dec 14, 2018
Maintained: Buy
Price Target: $168
Current: $146.18
Upside: n/a